Vincerx Pharma (NASDAQ:VINC) and Leap Therapeutics (NASDAQ:LPTX) Head-To-Head Analysis
by Scott Moore · The Cerbat GemVincerx Pharma (NASDAQ:VINC – Get Free Report) and Leap Therapeutics (NASDAQ:LPTX – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.
Insider & Institutional Ownership
44.0% of Vincerx Pharma shares are held by institutional investors. Comparatively, 30.5% of Leap Therapeutics shares are held by institutional investors. 15.6% of Vincerx Pharma shares are held by insiders. Comparatively, 4.3% of Leap Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Vincerx Pharma and Leap Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vincerx Pharma | N/A | N/A | -$40.16 million | ($5.31) | 0.00 |
| Leap Therapeutics | N/A | N/A | -$67.56 million | ($1.22) | -1.68 |
Leap Therapeutics is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Vincerx Pharma and Leap Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vincerx Pharma | 0 | 0 | 0 | 0 | 0.00 |
| Leap Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
Risk & Volatility
Vincerx Pharma has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500.
Profitability
This table compares Vincerx Pharma and Leap Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vincerx Pharma | N/A | -248.33% | -132.73% |
| Leap Therapeutics | N/A | -247.44% | -146.51% |
Summary
Vincerx Pharma beats Leap Therapeutics on 6 of the 9 factors compared between the two stocks.
About Vincerx Pharma
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.
About Leap Therapeutics
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.